Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Marvell Technology Inc (MRVL) vs ResMed Inc. (RMD) Price & Performance

Marvell Technology IncTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

Marvell Technology Inc vs ResMed Inc. — how do they compare? Marvell Technology Inc trades at $232.25 (market cap $200.91B), while ResMed Inc. trades at $219.5 (market cap $31.89B). The key difference: Marvell Technology Inc is far larger — about 6.3× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.19%). Which is the better fit depends on your goals.

MRVLRMD
Market Cap
$200.91B$31.89B
Sector
TechnologyHealth
52-Week High
$316.43$283.28
52-Week Low
$66.59$182.82
Enterprise Value
$202.26B$31.24B
Dividend Yield
0.11%1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Marvell Technology Inc

Marvell Technology (MRVL) trades at $225.41, up 0.83% with strong technical momentum and bullish moving average signals. The company demonstrates robust revenue growth with Q2 2026 EPS beating expectations at $0.94 versus $0.934, while management projects revenue reaching $12 billion this fiscal year and $18 billion next year. Analyst consensus remains overwhelmingly positive with 82% buy ratings and a $303.11 price target, representing 35% upside potential from current levels.

Marvell's AI-driven growth trajectory presents significant opportunity, though investors face risks from high valuation multiples (P/E 74.02) and competitive pressures in the semiconductor space. The stock's recent 31% pullback from yearly highs offers potential entry point for growth-oriented investors, supported by strong institutional accumulation and positive earnings momentum heading into October's Investor Day event.

ResMed Inc.

ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.

The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Marvell Technology Inc

Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.

Read more on MRVL

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD